一名肺腺癌患者在奥希替尼诱发肺炎后成功再次使用奥希替尼治疗。
Successful osimertinib rechallenge after osimertinib-induced pneumonitis in a patient with lung adenocarcinoma.
作者信息
Satoh Shingo, Shiroyama Takayuki, Tamiya Motohiro, Nasu Shingo, Tanaka Ayako, Morita Satomu, Morishita Naoko, Suzuki Hidekazu, Okamoto Norio, Hirashima Tomonori
机构信息
Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
出版信息
Respir Med Case Rep. 2017 Dec 11;23:68-70. doi: 10.1016/j.rmcr.2017.12.005. eCollection 2018.
Pneumonitis is a serious adverse event of EGFR-TKI treatment. Although several cases of EGFR-TKI rechallenge after EGFR-TKI-induced pneumonitis have been reported, little is known about post-pneumonitis osimertinib rechallenge. We describe a 69-year-old never-smoking Japanese woman with postoperative recurrent lung adenocarcinoma retreated with osimertinib after osimertinib-induced pneumonitis. Although osimertinib rechallenge must be carefully chosen based on risk/benefit analysis, osimertinib rechallenge after osimertinib-induced pneumonitis may be an option, with limited alternative therapeutic options.
肺炎是表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）治疗的一种严重不良事件。尽管已有几例关于EGFR-TKI诱导的肺炎后再次使用EGFR-TKI治疗的报道，但对于肺炎后再次使用奥希替尼治疗的情况知之甚少。我们描述了一名69岁从不吸烟的日本女性，她患有术后复发性肺腺癌，在奥希替尼诱导的肺炎后再次接受奥希替尼治疗。尽管必须基于风险/效益分析谨慎选择再次使用奥希替尼，但在奥希替尼诱导的肺炎后再次使用奥希替尼可能是一种选择，因为替代治疗选择有限。
Zotero 插件